Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
azacitidine + eltrombopag
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral, Subcutaneous, Intravenous
01
Overview
Azacitidine + eltrombopag is a combination therapy investigated primarily for the treatment of myelodysplastic syndromes (MDS) with thrombocytopenia. Azacitidine is a hypomethylating agent that incorporates into DNA and RNA, leading to cytotoxicity in abnormal hematopoietic cells and reactivation of silenced genes through DNA hypomethylation. Eltrombopag is an oral, nonpeptide thrombopoietin receptor agonist that stimulates platelet production by activating the thrombopoietin receptor (also known as MPL). The combination was studied to address azacitidine-induced or disease-related low platelet counts in MDS patients. However, phase 3 clinical trials showed that adding eltrombopag to azacitidine did not improve hematologic outcomes and was associated with worse overall survival compared to azacitidine alone[1][6][8].
- Brand names
- Alvaiz
- Other names
- eltrombopag + azacitidine
02
Targets
TPOR (Thrombopoietin receptor)DNMT (DNA methyltransferase)
Beyond the preview
Go deeper on azacitidine + eltrombopag.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on azacitidine + eltrombopag.